

2015

COME TRANSFORM RESEARCH

SLAS ASIA CONFERENCE AND EXHIBITION

CROWNE PLAZA CENTURY PARK
APRIL 9-10, 2015 | SHANGHAI



SLAS Asia 2015 Conference and Exhibition

Program Draft

Day 1, Thursday, 9 April	
08:45-09:00	SLAS Opening Remarks
09:00-09:45	Keynote 1: Going Fishing for Better Medicines Karl Barry Sharpless, Nobel Prize Laureate, W. M. Keck Professor of Chemistry, The Scripps Research Institute, California
09:45-12:45	Session 1: Leading Science for Small Molecules Drug Discovery Co-chairs: Jonanthan Connick, Executive Director, Head External in Vitro Pharmacology. Site Head, EDDS and PCD China, Merck & Co Inc. Bin Li, R&D Director, AbbVie China R&D Center
09:45-10:15	Discovery of GPR119 Agonist from Hoodia Xin Xie, Principle Investigator, Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Deputy Director, Chinese National Center for Drug Screening
10:15-10:45	Phenotypic Drug Discovery and Target Deconvolution Jing Li, Director of Pharmacology; Department of Screening and Protein Science; Merck Research Laboratories (MRL)
10:45-11:15	Break in Exhibit Hall
11:15-11:45	Discovery of HIV Integrase Inhibitors John Wai, Vice President of Medicinal Chemistry, WuXi AppTec (Shanghai)
11:45-12:45	Panel Discussion: Leveraging Technology and Tools to Enable Drug Discovery Moderator: Jonathan Connick, Executive Director, Head External in Vitro Pharmacology. Site Head, EDDS and PCD China, Merck & Co., Inc. Panelist: Pharma – Jing Li, Director of Pharmacology; Department of Screening and Protein Science; Merck Research Laboratories (MRL) CRO - Xuehai Tan, CEO & President, HD Biosciences Co., Ltd. Technology Provider – Joe Gu, LST APAC VP GM, Perkin Elmer Academia – tbc
12:45-14:30	Lunch in Exhibit Hall
12:45-14:30	Posters

13:45-14:30	Exhibitor Tutorial 1: To be defined	Exhibitor Tutorial 2: To be defined
14:30-17:00	Session 2: Natural Product Drug Discovery & Synthetic Biology Co-chairs: Bing Xie, Managing Director, Asia Pacific for Cisbio Bioassays Mike Zhang, Associate Sales Director, Research, BD Biosciences	
14:30-15:00	Discovery of NITD609 as Antimalarial: From Natural Product-like Lead to Clinical Candidate Bin Zou, Senior Medicinal Chemist, Novartis Institute for Tropical Diseases (Singapore)	
15:00-15:30	HTS Hits - Which Should You Discard, and Why? Jonathan Baell, Research Professor, Medicinal Chemistry, Monash Institute of Pharmaceutical Science	
15:30-16:00	Break in Exhibit Hall	
16:00-16:30	Anti-infective and Anti-tumor Natural Products Discovery and Biosynthesis from Marine Actinomycetes Jianhua Ju, Professor, South China Sea Institute of Oceanology, Chinese Academy of Sciences; Director, Guangdong Key Laboratory of Marine Materia Medica; Deputy Director, CAS Key Laboratory of Marine Bio-resources and Ecology	
16:30-17:00	Anti-infectious Natural Products from Marine-derived Microbes Xueting Liu, Associate Professor, CAS Key Laboratory of Pathogenic Microbiology & Immunology	
17:00-17:30	Topic tbc Hakim Djaballah	
17:30-19:00	Reception	

Day 2, Friday, 10 April	
08:45-09:00	Welcome Speech - Biologics Innovation Group (BiG) Annual Conference Bill Jiang Director, Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University
09:00-12:30	Session 3: The Scientific Frontier of Biological Discovery
Part I	Co-chairs: Ying Yang, Founder & CEO, LBD Life Sciences Ltd; Asian Council Chair, Society for Laboratory Automation and Screening (SLAS) Bill Jiang, Director, Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University
09:00-09:45	Keynote 2: Vaccine and Therapeutic Antibody for New Outbreak of Pathogen George Fu Gao, Director & Professor, Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences;

	Vice-President, Beijing Institutes of Life Science, Chinese Academy of Sciences; Deputy Director-General, Chinese Center for Disease Control and Prevention (China CDC)	
09:45-10:15	Virus and Anti-Virus Drug Discovery Zihe Rao, Biophysicist & Structural Biologist; Professor & Former President, Nankai University; Academician, Chinese Academy of Sciences; President, Biophysical Society of China; President-elect, International Union of Pure and Applied Biophysics (IUPAB)	
10:15-10:45	Break in Exhibit Hall	
Part II	Co-Chairs: Guang Yang, Vice Director, Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University Mingqiang Zhang, General Manager & Legal Representative, Amgen Biopharmaceutical Research and Development (Shanghai) Company Ltd.	
10:45-11:15	Systems Approach to Translational Medicine Genhong Cheng, Director, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences; Professor, Department of Microbiology, Immunology & Molecular Genetics, University of California Los Angeles	
11:15-11:45	Therapeutic Antibody Discovery and Lead Selection Yan Wu, Associate Director, Genentech	
11:45-12:30	Feature Talk and Panel Discussion: Case Study-NIBS's Technology Transfer and Commercialization of Scientific Findings Moderator: Chengbin Wu, CSO and President of R&D, Shanghai CP Guojian Pharmaceutical Co., Ltd. Speaker: Xiaodong Wang, Biochemist; Director & Investigator, National Institute of Biological Science, China; Member, National Academy of Sciences, USA Panelist: Mingqiang Zhang, General Manager & Legal Representative, Amgen Biopharmaceutical Research and Development (Shanghai) Company Ltd. Fritjof Linz, VP Head of Biologics CMC and Business Development, ChemPartner Bill Jiang, Director, Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University	
12:30-14:00	Lunch in Exhibit Hall	
12:30-14:00	Posters	
13:15-14:00	Exhibitor Tutorial 3 Location: Nanjing Room, Level 5 Sponsored by  analytikjena 德国耶拿	Exhibitor Tutorial 4 Location: Suzhou Room, Level 5 Sponsored by  TECAN .
14:00-17:30	Session 4: ADC - From Technology, Process, Discovery, to Development	
Part I	Co-chairs: Xueming Qian, Chairman & CEO, Mabspace Biosciences CO., LTD Fritjof Linz, VP Head of Biologics CMC and Business Development, ChemPartner	

14:00-14:30	Antibody-Drug Conjugates for Cancer Therapy: Deliver the Promise Weikang Tao, CEO, Shanghai HengRui Medicine Co., Ltd., R&D Center
14:30-15:00	Site Specific Conjugation: Improvement of ADC Homogeneity and Druggability Properties Bruce Nianhe Han, CSO, NewBio Therapeutics
15:00-15:30	R&D of Next-generation ADCs Based on LDC Technology Gang Qin, Cofounder & CEO, GeneQuantum Healthcare (Suzhou) Co., Ltd.
15:30-16:00	Biological Characterization of Antibody Drug Conjugates Mary Hu, CEO, Shanghai Miracogen Inc.
16:00-16:30	Break in Exhibit Hall
Part II	Co-chairs: Zhenping Zhu, Executive Vice President, Global Biopharmaceuticals, Kadmon Corporation (New York); President, Kadmon China Chengbin Wu, CSO and President of R&D, Shanghai CP Guojian Pharmaceutical Co., Ltd.
16:30-17:00	A New Generation of Antibody-drug Conjugates for the Targeted Treatment of Cancer Robert Yongxin Zhao, CEO & Chairman, Hangzhou DAC Biotech Co., Ltd.
17:00-17:30	Developing a Novel ADC for Global Market via Innovative Three-party Collaboration Chris Chen, Head of Biologics, WuXi AppTec
17:30-17:45	Closing Remark (awarding)